Canaccord analyst Edward Nash downgraded Dice Therapeutics (DICE) to Hold from Buy with a price target of $48, down from $71, after Eli Lilly (LLY) agreed to acquire the company for $48 per share.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DICE:
- Dice Therapeutics price target raised to $48 from $38 at Wells Fargo
- DICE Surges after $2.4 Billion Acquisition by LLY
- Eli Lilly to acquire Dice Therapeutics for $48 per share in cash
- Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
- DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
